Skip to content
CancerIndex

Publication

Anticancer Efficacy of HPPH-PDT Synergies with BCG-Immunotherapy or COX-2 Inhibitor in Treating Bladder Cancer.

Farukh A Durrani, Joseph Cacaccio, William Potter, Mykhaylo Dukh, Mehrgan Ghazaeian, Ahmed A Hussein, Omar M Ibrahim, Pawel Kalinski, Paras N Prasad, Heinz Baumann, Khurshid A Guru, Ravindra K Pandey

Molecular pharmaceuticsSep 7, 2026PMID 41920055doi:10.1021/acs.molpharmaceut.5c01678 Journal ArticlepubmedProvenance
Source
PubMed
Retrieved
Sep 16, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260916-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Among the photosensitizers (PSs) developed in our laboratory, 3-(1'-hexyloxy) ethyl-3-devinyl pyropheophorbide-a (HPPH) is undergoing Phase-II multicenter clinical trials for the treatment of head and neck and esophageal cancers. The PS exhibits absorption at 665 nm (in vivo) and shows desired…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.